PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+18.83%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$2.67B
AUM Growth
+$2.67B
(-5.5%)
Cap. Flow
-$524M
Cap. Flow
% of AUM
-19.65%
Top 10 Holdings %
Top 10 Hldgs %
54.89%
Holding
105
New
17
Increased
12
Reduced
35
Closed
21
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$166M |
| 2 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$44.4M |
| 3 |
Roivant Sciences
ROIV
|
$37.5M |
| 4 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$29.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
$19.5M |
Top Sells
| 1 |
Lyra Therapeutics
LYRA
|
$112M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$104M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$99.9M |
| 4 |
Soleno Therapeutics
SLNO
|
$90.2M |
| 5 |
Amicus Therapeutics
FOLD
|
$80.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.16B
| $521M | 19.31% | 5,507,591 -1,055,749 | -16% | -$99.9M |
|
|
2
Ascendis Pharma
ASND
$11.8B
| $166M | 6.17% | +963,886 | New | +$166M |
|
3
Arcellx
ACLX
$3.85B
| $163M | 6.05% | 2,478,000 -448,478 | -15% | -$29.5M |
|
4
Rhythm Pharmaceuticals
RYTM
$6.85B
| $153M | 5.67% | 2,418,299 -130,146 | -5% | -$8.22M |
|
5
Nuvalent
NUVL
$5.52B
| $105M | 3.89% | 1,375,180 -258,788 | -16% | -$19.7M |
|
6
Artivion
AORT
$2.07B
| $86.9M | 3.22% | 2,793,703 | – | – |
|
7
MeiraGTx Holdings
MGTX
$587M
| $82.2M | 3.05% | 12,626,103 +45,000 | +0.4% | +$293K |
|
8
Insmed
INSM
$28.8B
| $65.4M | 2.43% | 650,252 +140,952 | +28% | +$14.2M |
|
9
Edgewise Therapeutics
EWTX
$1.51B
| $60.8M | 2.26% | 4,639,949 -1,907,379 | -29% | -$25M |
|
10
Protagonist Therapeutics
PTGX
$3.67B
| $59.4M | 2.2% | 1,074,448 -16,823 | -2% | -$930K |
|
11
Solid Biosciences
SLDB
$427M
| $58M | 2.15% | 11,906,646 | – | – |
|
12
Apogee Therapeutics
APGE
$2.17B
| $51.3M | 1.9% | 1,182,148 +59,381 | +5% | +$2.58M |
|
13
Amylyx Pharmaceuticals
AMLX
$836M
| $50.7M | 1.88% | 7,902,365 +28,017 | +0.4% | +$180K |
|
14
Immatics
IMTX
$619M
| $50.5M | 1.87% | 9,383,456 | – | – |
|
15
Akero Therapeutics
AKRO
$3.74B
| $48.9M | 1.81% | 915,887 +122,927 | +16% | +$6.56M |
|
|
OMDA
16
Omada Health, Inc. Common Stock
OMDA
$1.36B
| $44.4M | 1.65% | +2,426,330 | New | +$44.4M |
|
|
17
Amicus Therapeutics
FOLD
$2.34B
| $42.5M | 1.57% | 7,412,830 -14,051,697 | -65% | -$80.5M |
|
|
18
Roivant Sciences
ROIV
$8.15B
| $37.5M | 1.39% | +3,331,465 | New | +$37.5M |
|
19
Merus
MRUS
$4.98B
| $37.3M | 1.38% | 708,176 +17,691 | +3% | +$931K |
|
|
20
Soleno Therapeutics
SLNO
$3.6B
| $36.1M | 1.34% | 430,439 -1,076,163 | -71% | -$90.2M |
|
21
Astria Therapeutics
ATXS
$349M
| $34.8M | 1.29% | 6,485,420 | – | – |
|
22
Immunovant
IMVT
$2.56B
| $34.2M | 1.27% | 2,137,890 -706,182 | -25% | -$11.3M |
|
|
23
Neurocrine Biosciences
NBIX
$13.8B
| $32.1M | 1.19% | 255,050 +155,000 | +155% | +$19.5M |
|
24
Praxis Precision Medicines
PRAX
$958M
| $31.7M | 1.17% | 752,921 -227,973 | -23% | -$9.59M |
|
25
Boston Scientific
BSX
$156B
| $30.1M | 1.12% | 280,000 +150,000 | +115% | +$16.1M |
|